CO6351791A2 - "derivados de purina para uso en el tratamiento de enfermedades alergias, inflamatorias e infecciosas" - Google Patents

"derivados de purina para uso en el tratamiento de enfermedades alergias, inflamatorias e infecciosas"

Info

Publication number
CO6351791A2
CO6351791A2 CO11005402A CO11005402A CO6351791A2 CO 6351791 A2 CO6351791 A2 CO 6351791A2 CO 11005402 A CO11005402 A CO 11005402A CO 11005402 A CO11005402 A CO 11005402A CO 6351791 A2 CO6351791 A2 CO 6351791A2
Authority
CO
Colombia
Prior art keywords
treatment
infectious diseases
inflammatory
allergy
purine derivatives
Prior art date
Application number
CO11005402A
Other languages
English (en)
Inventor
Keith Biggadike
Diane Mary Coe
Xiao Qing Lewell
Charlotte Jane Mitchell
Stephen Allan Smith
Naimisha Trivedi
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41187189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351791(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CO6351791A2 publication Critical patent/CO6351791A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de fórmula (I):en la que R1 es alquil C1-6-amino, alcoxi C1-6 o cicloalquiloxi C3-7; m es un número entero que tiene un valor de 3 a 6; n es un número entero que tiene un valor de 0 a 4; y las sales de los mismos son inductores de interferón humano. Los compuestos que inducen interferón humano pueden ser útiles en el tratamiento de diversos trastornos, por ejemplo, el tratamiento de enfermedades alérgicas y otras afecciones inflamatorias, por ejemplo, rinitis alérgica y asma, el tratamiento de enfermedades infecciosas y cáncer, y también pueden ser útiles como adyuvantes de vacunas.
CO11005402A 2008-08-11 2011-01-19 "derivados de purina para uso en el tratamiento de enfermedades alergias, inflamatorias e infecciosas" CO6351791A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8777708P 2008-08-11 2008-08-11

Publications (1)

Publication Number Publication Date
CO6351791A2 true CO6351791A2 (es) 2011-12-20

Family

ID=41187189

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11005402A CO6351791A2 (es) 2008-08-11 2011-01-19 "derivados de purina para uso en el tratamiento de enfermedades alergias, inflamatorias e infecciosas"

Country Status (38)

Country Link
US (7) US8067426B2 (es)
EP (3) EP3336089A1 (es)
JP (1) JP5529867B2 (es)
KR (1) KR101669939B1 (es)
CN (2) CN102177159B (es)
AU (1) AU2009281197B2 (es)
BR (1) BRPI0917138A2 (es)
CA (1) CA2733749C (es)
CL (1) CL2011000301A1 (es)
CO (1) CO6351791A2 (es)
CR (1) CR20110116A (es)
CY (1) CY1119992T1 (es)
DK (2) DK2324026T3 (es)
DO (1) DOP2011000048A (es)
EA (1) EA020631B1 (es)
ES (2) ES2661671T3 (es)
HK (3) HK1157770A1 (es)
HR (2) HRP20150938T1 (es)
HU (2) HUE036570T2 (es)
IL (1) IL210757A (es)
LT (1) LT3000813T (es)
MA (1) MA32624B1 (es)
ME (1) ME02274B (es)
MX (2) MX336345B (es)
MY (1) MY162538A (es)
NO (1) NO3000813T3 (es)
NZ (2) NZ590782A (es)
PE (1) PE20110674A1 (es)
PL (2) PL2324026T3 (es)
PT (2) PT3000813T (es)
RS (2) RS54266B1 (es)
SG (1) SG192547A1 (es)
SI (2) SI3000813T1 (es)
SM (1) SMT201500224B (es)
TR (1) TR201802648T4 (es)
UA (1) UA103195C2 (es)
WO (1) WO2010018133A1 (es)
ZA (1) ZA201100845B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI414525B (zh) * 2004-03-26 2013-11-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
EP1874772A1 (en) * 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
WO2007034817A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
CL2008000496A1 (es) * 2007-02-19 2008-09-22 Smithkline Beecham Corp Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias.
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
WO2008114006A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
EP2138497A4 (en) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
WO2008135791A1 (en) * 2007-05-08 2008-11-13 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
MX2009013832A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8865896B2 (en) * 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
JPWO2009091031A1 (ja) * 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
WO2010018130A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
EA019204B1 (ru) 2008-08-11 2014-01-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные аденина и их применение в терапии
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
DK2534149T3 (da) * 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
EP2575773A4 (en) 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
ES2575688T3 (es) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
WO2012149393A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
EP2734186B1 (en) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Composition
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
UA114109C2 (xx) 2012-08-24 2017-04-25 Піразолопіримідинові сполуки
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
PL2922549T3 (pl) * 2012-11-20 2017-11-30 Glaxosmithkline Llc Nowe związki
CA2890198A1 (en) * 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
CN104780924B (zh) 2012-11-20 2016-09-14 葛兰素史克有限责任公司 干扰素诱导剂化合物
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
ES2655940T3 (es) * 2014-02-20 2018-02-22 Glaxosmithkline Intellectual Property (No. 2) Limited Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EP3160453A1 (en) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
JP2017533925A (ja) * 2014-11-13 2017-11-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
US20190380977A1 (en) * 2016-05-23 2019-12-19 University Of Iowa Research Foundation Method of treating cystic fibrosis airway disease
AR108665A1 (es) * 2016-06-02 2018-09-12 Celgene Corp Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania
US11253476B2 (en) 2017-03-29 2022-02-22 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
CN108948016B (zh) * 2017-05-19 2021-02-26 江苏恒瑞医药股份有限公司 嘌呤酮类衍生物、其制备方法及其在医药上的应用
WO2019099564A1 (en) 2017-11-14 2019-05-23 Children's Medical Center Corporation Novel imidazopyrimidine compounds and uses thereof
US11730810B2 (en) 2017-11-14 2023-08-22 Children's Medical Center Corporation Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response
WO2019097696A1 (ja) 2017-11-17 2019-05-23 株式会社Ｎｔｔドコモ ユーザ端末及び無線通信方法
JP7506981B2 (ja) 2017-12-21 2024-06-27 住友ファーマ株式会社 Ｔｌｒ７アゴニストを含む併用薬
KR20210034614A (ko) 2018-07-23 2021-03-30 국립감염증연구소장이 대표하는 일본국 인플루엔자 백신을 포함하는 조성물
US11486970B1 (en) 2019-02-11 2022-11-01 Innovusion, Inc. Multiple beam generation from a single source beam for use with a LiDAR system
BR112021023292A2 (pt) 2019-05-23 2022-02-08 The Univ Of Montana Composto, formulação, composição de vacina, composição farmacêutica, e, método para modular uma resposta imune em um indivíduo
US20220242866A1 (en) * 2019-06-24 2022-08-04 Merck Sharp & Dohme Corp. Process for the preparation of 2-fluoroadenine
CN110772523B (zh) * 2019-11-07 2020-06-26 黑龙江中医药大学 一种用于防治肾病的药物组合物
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1065213A3 (en) 1999-07-02 2003-11-05 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
AU5919001A (en) 2000-04-28 2001-11-12 Acadia Pharm Inc Muscarinic agonists
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
CA2434386C (en) 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CN1533390A (zh) 2001-03-19 2004-09-29 СҰҩƷ��ҵ��ʽ���� 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003003130A1 (fr) 2001-06-29 2003-01-09 Trigger Co.Ltd. Montre-bracelet radio
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
DK1348707T3 (da) 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
AU2003260578A1 (en) 2002-04-04 2003-10-20 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
EP1501850A2 (en) 2002-05-06 2005-02-02 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US6713241B2 (en) 2002-08-09 2004-03-30 Eastman Kodak Company Thermally developable emulsions and imaging materials containing binder mixture
CN100379750C (zh) 2002-08-21 2008-04-09 阿尔伯爱因斯坦医科叶希瓦大学 核苷磷酸化酶和核苷酶抑制剂
US7754728B2 (en) 2002-09-27 2010-07-13 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound and use thereof
BR0315417A (pt) 2002-10-24 2005-08-16 Glaxo Group Ltd Derivados 1-acil-pirrolidina para o tratamento de infecções virais
WO2004054974A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
AU2003296992A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
ATE410426T1 (de) 2002-12-13 2008-10-15 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
AU2004271972B2 (en) 2003-09-05 2010-06-03 Anadys Pharmaceuticals, Inc. TLR7 ligands for the treatment of hepatitis C
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
ATE514682T1 (de) 2003-12-01 2011-07-15 Oreal 4-5-diamino-n,n-dihydro-pyrazol-3-on-derivate und deren verwendung als färbemittel für keratinfasern
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
TWI414525B (zh) * 2004-03-26 2013-11-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
US20070225303A1 (en) * 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
JP4691020B2 (ja) 2004-03-31 2011-06-01 株式会社湯山製作所 錠剤フィーダ
PT1740591E (pt) 2004-04-02 2009-09-24 Osi Pharm Inc Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6
JP2007534735A (ja) 2004-04-28 2007-11-29 アロウ セラピューティクス リミテッド 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AP2313A (en) 2004-08-18 2011-10-31 Pfizer Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
EP1799256A4 (en) 2004-08-27 2009-10-21 3M Innovative Properties Co METHOD FOR PROVIDING AN IMMUNE RESPONSE AGAINST HIV
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
EA200702235A1 (ru) * 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
WO2007013964A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
KR20080039982A (ko) 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
EA200800396A1 (ru) 2005-09-02 2008-08-29 Пфайзер Инк. Гидроксизамещенные 1н-имидазопиридины и способы
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2007034817A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US20090105212A1 (en) * 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP1939200A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20090192153A1 (en) * 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
JPWO2007034882A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
ATE532784T1 (de) 2006-02-17 2011-11-15 Pfizer Ltd 3-deazapurinderivate als tlr7-modulatoren
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
US20070282962A1 (en) 2006-06-01 2007-12-06 Microsoft Corporation Auto-Subscribing to Syndication Feeds Using Contact Lists
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
AU2007269557B2 (en) * 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
CL2008000496A1 (es) 2007-02-19 2008-09-22 Smithkline Beecham Corp Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias.
WO2008114006A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
PT2132209E (pt) 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
MX2009013832A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
EA019204B1 (ru) 2008-08-11 2014-01-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные аденина и их применение в терапии
KR20110042116A (ko) 2008-08-11 2011-04-22 글락소스미스클라인 엘엘씨 알레르기성, 염증성 및 감염성 질환의 치료에서 사용하기 위한 푸린 유도체
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
WO2010018130A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2010083725A1 (zh) 2009-01-20 2010-07-29 山东轩竹医药科技有限公司 含有取代的含氮稠杂环的头孢菌素衍生物
JP5759992B2 (ja) 2009-08-07 2015-08-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 脂質付加オキソアデニン誘導体
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012092552A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
EP2670733B1 (en) 2011-02-01 2019-04-10 The Board of Trustees of the University of Illionis N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2734186B1 (en) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Composition
UA114109C2 (xx) 2012-08-24 2017-04-25 Піразолопіримідинові сполуки
PL2922549T3 (pl) 2012-11-20 2017-11-30 Glaxosmithkline Llc Nowe związki
CN104780924B (zh) 2012-11-20 2016-09-14 葛兰素史克有限责任公司 干扰素诱导剂化合物
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
ES2655940T3 (es) 2014-02-20 2018-02-22 Glaxosmithkline Intellectual Property (No. 2) Limited Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano

Also Published As

Publication number Publication date
US20140336175A1 (en) 2014-11-13
KR20110042230A (ko) 2011-04-25
SMT201500224B (it) 2015-10-30
EA020631B1 (ru) 2014-12-30
NZ602812A (en) 2014-04-30
HUE036570T2 (hu) 2018-07-30
EP2324026A1 (en) 2011-05-25
PT2324026E (pt) 2015-10-22
US20160228445A1 (en) 2016-08-11
ZA201100845B (en) 2012-07-25
JP5529867B2 (ja) 2014-06-25
DK2324026T3 (en) 2015-09-21
HK1253532A1 (zh) 2019-06-21
BRPI0917138A2 (pt) 2015-11-17
RS56984B1 (sr) 2018-05-31
HK1222857A1 (zh) 2017-07-14
US9233962B2 (en) 2016-01-12
LT3000813T (lt) 2018-03-12
AU2009281197A1 (en) 2010-02-18
CN102177159A (zh) 2011-09-07
US9877968B2 (en) 2018-01-30
US20110229500A1 (en) 2011-09-22
KR101669939B1 (ko) 2016-10-27
SI2324026T1 (sl) 2015-10-30
DK3000813T3 (da) 2018-01-29
NO3000813T3 (es) 2018-05-12
CA2733749C (en) 2016-10-11
CL2011000301A1 (es) 2011-07-15
PL3000813T3 (pl) 2018-05-30
MX336345B (es) 2016-01-15
EP2324026B1 (en) 2015-07-08
SI3000813T1 (en) 2018-03-30
US20190038631A1 (en) 2019-02-07
US8765772B2 (en) 2014-07-01
US20100075995A1 (en) 2010-03-25
HUE027637T2 (en) 2016-11-28
EP3000813B1 (en) 2017-12-13
MX2011001666A (es) 2011-03-24
RS54266B1 (en) 2016-02-29
HRP20180202T1 (hr) 2018-03-09
IL210757A (en) 2014-09-30
AU2009281197B2 (en) 2014-09-11
CN102177159B (zh) 2014-07-23
PE20110674A1 (es) 2011-10-07
MA32624B1 (fr) 2011-09-01
ES2661671T3 (es) 2018-04-03
US8067426B2 (en) 2011-11-29
US20180117048A1 (en) 2018-05-03
CN104098568B (zh) 2016-08-17
UA103195C2 (uk) 2013-09-25
EP3000813A1 (en) 2016-03-30
CY1119992T1 (el) 2018-12-12
CN104098568A (zh) 2014-10-15
HK1157770A1 (en) 2012-07-06
DOP2011000048A (es) 2011-03-31
EP3336089A1 (en) 2018-06-20
PT3000813T (pt) 2018-03-05
HRP20150938T1 (hr) 2015-10-09
TR201802648T4 (tr) 2018-03-21
NZ590782A (en) 2012-10-26
SG192547A1 (en) 2013-08-30
PL2324026T3 (pl) 2015-11-30
US9346806B2 (en) 2016-05-24
CR20110116A (es) 2011-07-28
JP2011530563A (ja) 2011-12-22
CA2733749A1 (en) 2010-02-18
EA201100113A1 (ru) 2011-10-31
MY162538A (en) 2017-06-15
ES2549154T3 (es) 2015-10-23
IL210757A0 (en) 2011-03-31
WO2010018133A1 (en) 2010-02-18
US20120035193A1 (en) 2012-02-09
US10117873B2 (en) 2018-11-06
ME02274B (me) 2016-02-20

Similar Documents

Publication Publication Date Title
CO6351791A2 (es) "derivados de purina para uso en el tratamiento de enfermedades alergias, inflamatorias e infecciosas"
EA201100114A1 (ru) Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
DOP2015000121A (es) Compuestos novedosos
DOP2015000027A (es) Compuestos de pirazolopirimidinas
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
EA201290631A1 (ru) Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
BR112015011439A2 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA201100115A1 (ru) Новые производные аденина
UY33950A (es) Inhibidores de benzodioxano de la producciòn de leucotrieno
UY35139A (es) 4- (orto) -fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
AR074754A1 (es) Derivados de purina-8-ona
UY32356A (es) Compuestos inductores del interferón humano y sus usos
CY1116844T1 (el) Παραγωγα πουρινης για χρηση στη θεραπεια αλλεργικων, φλεγμονωδων και μολυσματικων ασθενειων
TH148547B (th) อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ
JO3094B1 (ar) مشتقات بيورين للاستخدام في علاج أمراض تحسسية والتهابية ومعدية
TH157360A (th) สารประกอบใหม่
CY1116091T1 (el) Μηλεϊνικη 6-αμινο-2-{[(1s)-1-μεθυλβουτυλ]οξυ}-9-[5-(1-πιπεριδινυλ)πεντυλ]-7,9-διυδρο-8η-πουριν-8-ονη
TH155660A (th) สารประกอบพิแรโซโลพิริมิดีน
CU20110002A7 (es) Derivados de triazol útiles para el tratamiento de enfermedades

Legal Events

Date Code Title Description
FC Application refused